BRII-179 showed 32% HBsAg loss durability at 24 weeks post-treatment in the Phase 2b ENRICH study, with consistent results ...
Eton's ET-700 shows better tolerability than GALZIN but reduced efficacy in Wilson disease pilot study with 12 patients per ...
ATG-201 Phase I trial opens in China for B cell autoimmune diseases, testing a CD19×CD3 bispecific with masking technology to ...
ICON's AI-directed video engine cuts clinical trial video production time by 90%, streamlining site selection and training ...
Citius Oncology presents LYMPHIR quality-of-life data from pivotal Study 302 at EORTC meeting, supporting formulary ...
Ivonescimab perioperative NSCLC study shows 50.7% pathological complete response rate, outpacing current standard-of-care ...
Clinical research sites report trial complexity as their top operational problem, with 41% naming it their biggest challenge ...
PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...
Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...
CluePoints positions RBQM architecture as the structural foundation for clinical monitoring, consolidating evidence across ...
PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...
The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results